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Summary: A simple, rapid, quantitative, low-cost UV-differential spectrophotometric method for the routine
monitoring of phenobarbitai in serum and cerebrospinal fluid is described. This method can also be used for moni-
toring methylphenobarbital (Phemiton) and primidone (Mysoline), since the major active metabolite of both drugs
is phenobarbitai. The basis for our procedure is Goldbaum's method (Anal. Chem., 24, 1604 (1952)). This method
was improved with several modifications including a single extraction technique with dichloroethane, which has
produced a very simple but still accurate method. The whole analysis takes less than 20 minutes. This procedure is
accurate in the range from 1—100 mg/1 of phenobarbitai in serum or cerebrospinal fluid.
Verbesserte UV-spektrophotometrische Methode zur routinemäßigen Kontrolle von Barbituratkonzentrationen
Zusammenfassung: Eine einfache, schnelle, quantitative und billige UV-spektrophotometrische Differenzmethode
zur routinemäßigen Kontrolle der PhenobarbitaHConzentration in Serum und Liquor wird beschrieben. Diese Methode
kann auch zur Kontrolle der Konzentrationen von Methylphenobarbital (Phemiton) und Primidon (Mysoline) ange-
wandt werden, da der Hauptmetabplit beider Pharmaka Phenobarbitai ist. Grundlage für unser Verfahren ist die
Methode von Goldbaum (Anal. Chem. 24, 1604 (1952)). Durch mehrfache Modifikation einschließlich Extraktion
mit Dichlorethan wurde das Verfahren zu einer sehr einfachen, dennoch genauen Methode verbessert. Die gesamte
Analyse dauert weniger als 20 Minuten. Das Verfahren ist genau im Bereich von 1—100 mg/1 Phenobarbitai in Serum
oder Liquor.
Introduction
The primary goals in the utilization of serum anticon-
vulsant drug levels in the management of patients with
seizure disorders are to achieve either a reduction in
the toxic effects or an improvement in the therapeutic
effect secondary to the administration of these drugs.
There may be considerable variability in the serum antL·
convülsant levels in patients receiving identical doses
of drug under standardized conditions (1). Only when
the time course of pharmacologic effects can be related
quantitatively to the time course of drug concentrations
in the serum will it be possible to develop the most
rational dosage regimens for safe and effective therapy,
and to make appropriate adjustments of dosage in
accordance with individual differences in drug meta*
holism and response.
In this paper a simple spectrophotometric method for
routine phenqbarbital serum and cerebrospinal fluid
level monitoring is described. Methylphenobarbital
(Phemiton) is almost completely metabolized in man
to phenobarbitai (2). The present concept of primidone
(Mysoline) metabolism in humans includes its conversion
to two major metabolites, phenobarbitai and phenyl-
ethylmalonamide (3). Therefore, the methylpheno-
barbital serum level, as well as the primidone serum




Double-beam UV-spectrophotometer UNICAM SP 1800 with
recorder. Any other UV-spectrophotometer with or without
J. Clin. Chem. Clin. Biochem. / Vol. 14, 1976 / No. 10 34·
480 Jeremic and Nikolic: An improved UV-spectrophotometric method for routine barbiturate monitoring
recorder can be used. Semimicro silica cells. Separating funnels
for extraction.
Reagents
Chemicals and solvents were of reagent-grade quality. Redistilled
water was used. Dichloroethane was purified before use. For
this purpose, 25 ml of dichloroethane were washed with 10 ml
of NaOH (0.1 mol/1) for 3 minutes. The phases were allowed to
separate and the organic (lower) layer was drained to another
separating funnel and washed twice with 10 ml of redistilled
water. \Vashing with dilute alkali, than with water, is important
especially when using chloroform or dichlorethane which
decompose on standing. The decomposition products may have
appreciable ultraviolet absorption but are effectively removed
by an alkali wash.
Standards
The stock solution (1 g/1):
Dissolve 10 mg of phenobarbital in 0.5 ml of NaOH (0.45 mol/1),
and dilute to 10 ml with Stfrensen's phosphate buffer (0.067
mol/1) pH 7.4.
Working phenobarbital standards (10, 20, 30, 50 and 100 mg/1):
Dilute 0.5,1.0,1.5, 2.5, and 5.0 ml of the stock solution to 50 ml
with pooled drug-free serum or cerebrospinal fluid.
Extract with dichloroethane
1
Extract with 0,45 m a l / I N a O H
I
N a O H extract
*300 g/ l N H 4 C l
N a O H extract
*0,45mol/ l N a O H
Record the d i f fe ren t i a l spectrum
f rom 200 to 300 nm
Samples
The blood samples were withdrawn by venous puncture and
collected in glass tubes without addition of anticoagulants.
The cerebrospinal fluid was obtained by lumbar puncture.
Fig. 1. Flow diagram of full procedure.
CSF = Cerebrospinal fluid.
Assay principle
Phenobarbital in serum and cerebrospinal fluid is determined by
extraction of the alkaline (pH 13.0) and acidified (pH 10.5)
extract. The difference in absorbance between the pH 13.0 and
pH 10.5 solutions at 260 nm is proportional to phenobarbital
concentration in the sample (4).
Assay procedure
Extraction
A complete block diagram of the procedure is given in figure 1.
A measured volume of the serum or cerebrospinal fluid (2 ml
samples are taken) is transferred to a separating funnel, 25 ml of
previously purified dichloroethane is added, and the mixture
shaken gently for 5 minutes. The aqueous (upper) phase is
decanted off and the organic layer is transferred to another
separating funnel. 3 ml of NaOH (0.45 mol/1) are added, and1
mixture shaken gently for 5 minutes. The organic (lower) phase
is discarded, and the alkaline upper layer is drained to a centrifuge
tube and centrifuged for 10 minutes at 2000 rpm. Any dichloro-
ethane present will precipitate at the bottom and the supernatant
is the alkaline extract. In none of the sera from the patients
examined have we noted turbidity in the final alkaline extracts.
Results
Figure 2 shows the differential spectra of a number of
concentrations of phenobarbital, obtained after extraction
of sera or cerebrospinal fluid of patients treated with
phenobarbital, methylphenobarbital and primidone.
They all give a single peak at 260 nm.
Standard curve and blanks
Figure 3 shows a phenobarbital calibration curve. The
absorbance at 260 nm is linearly related to the pheno^
barbital concentrations over the range 1.0 to 100.0 mg/1.
None of the blank serum and cerebrospinal fluid samples
carried through the entire extraction procedure had peaks
at 260 nm.
Spectrophotometric measurement
To each of two semimicro silica cells 1 ml of the alkaline extract
is transferred. To the reference cell 0.1 ml of NH4C1 (300 g/l)
is added. The same volume of NaOH (0.45 mol/1) is added to the
sample cell, and the differential spectrum from 200 to 300 nm
is recorded. When working without a recorder, the absorbance at
260 nm is measured.
Quantitation
The phenobarbital level was estimated by preparing a calibration
curve with phenobarbital working serum or cerebrospinal fluid
standards containing 10, 20, 30,50 and 100 mg/1.
Recovery
Recovery of phenobarbital was determined by comparing
the absorbance at 260 nm of extracted standards with the
absorbance at 260 nm obtained with an unextracted
aqueous solution of phenobarbital (20 mg/1). After
correction for aliquot factors, the actual recovery of
phenobarbital from serum or cerebrospinal fluid was
more than 90%. The percentage recovery decreased
when standards containing less than 10;mg/l were
examined.
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Fig. 3. Phenobarbital calibration curve. Absorbance was measured
in a semimicro silica cells in a double-beam UV-spectro-
photometer NICAM SP 1800. Reference cell: pH 10.5;
sample cell: pH 13.0. The points shown represent mean
± 1 S.D.
Fig. 2. a) Differential absorption spectrum of serum (A) of
patient treated with phenpbarbital (3.3 mg/kg body
weight). Differential absorption spectrum (B) of pherip-
barbital standard (20 mg/1).
b) Differential absorption spectra of serum (A) and
cerebrospirial fluid (B) of patient treated with methyl-
phenolbarbital (Phemiton, 5.17 mg/kg body weight).
c)D.ifferential absorption spectra of sera of patients
treated with primidone (Mysoline):
(A) 25.0 mg/kg of body weight,
(B) 7.8 mg/kg of body weight.
Sensitivity
The practical limit of sensitivity for the method as
described is 1.0 mg/1 of phenobarbital in serum or
cerebrospinal fluid.
Precision
The coefficient of variation obtained by extraction and
analysis of eight replicate working standards (20 mg/1)
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was less than 1.5%. Reproducibility did not vary signi-
ficantly from day to day.
Specificity of the assay
The serum and cerebrospinal fluid samples from patients
on antiepileptic treatment were analyzed as described
above. The identity of the drug-related peaks was con-
firmed by the thin-layer chromatography. The RF-values
of phenobarbital extracted from sera and cerebrospinal
fluid are identical to its respective standard. The serum
extracts from patients treated with various drugs, such
as: pyrithioxin (Encephabol), nitrazepam (Mogadon),
methotrimeprazine maleate (Nozinan), biperiden hydro-
chloride (Akineton) and Meprobamate showed no peak
at 260 nm when analyzed as described. To test the speci-
fity of the assay against the common antiepileptic drugs,
we prepared sera containing phenobarbital at a concen-
tration of 20 mg/1 and added one of the following anti-
epileptic drugs to each sample: diphenylhydantoin
(Dilantin), carbamazepine (Tegretol), ethosuximide
(Zarontin), Sulthiame (Ospolot), diazepam (Valium),
barbital, butobarbital, amylobarbital. The samples were
analyzed as described and we saw no interference in the
assay, except for the 5,5-disubstituted barbiturates, which
have the same differential spectra, there being small
variations in the wavelengths of the absorption maxima.
Since it is not recommended in the treatment of epileptic
patients to combine two drugs with the same action and
similar properties, such interference is of small practical'
importance.
Discussion
Over the past decade, clinicians have accepted the value
of regular blood level measurements in antiepileptic drug
therapy. Phenobarbital is one of the most frequently
used antiepileptic drugs. Effective use of the drug
depends on maintaining the proper blood concentra-
tion. Blood level measurements have become recognized
as being valuable in adjusting and maintaining dosage
schedules (1). Determination of serum level in a patient
seen for the first time is also helpful. It gives an early and
fair estimate of the reliability of the patient in taking
his medications. The almost universal tendency of
patients is that they are erratic in taking prescribed
doses. The availability of serum levels allows better
supervision of the actual doses taken, and makes it
possible to significantly increase the serum levels in
many patients whose original levels were low. The anti-
epileptic drug monitoring indicates which drug might
reasonably be increased if seizures continue. The chronic
use of these drugs in the therapy of epilepsy maximizes
the probability that a potential toxicity will be realized.
Drug monitoring suggest which drug is present in large
amounts, and might be contributing to toxicity or might
do so if the dose were raised.
A number of analytical methods for measuring pheno-
barbital blood levels are in use today and have been
reviewed by Rose et al. (5). Although these methods
are sensitive, they are time-consuming, difficult to per-
form and not routinely available. As a result, blood
level measurements of antiepileptic drugs are not
commonly used by clinicians treating seizure disorders.
The choice of any analytical technique or method for
the detection of antiepileptic drugs must take into con-
sideration the purpose for which the analysis is performed,
e. g. routine urine screening, toxicology, drug moni-
toring or hospital emergencies. Initially, quantitative
serum measurements of antiepileptic drugs were
attempted by colorimetric, UV-spectrophotometric
and thin-layer Chromatographie methods. More recently,
gas liquid chromatography has become the most common
analytical methodology (6). The thin-layer Chromato-
graphie procedures are not truly quantitative; they are
principally advantageous for toxicity screening tests.
While gas liquid chromatography is sensitive and accurate
(if performed properly) the method is complex, time-
consuming and quite sensitive to operator skill and
sample preparatory procedures. As a result, serum drug
measurements with gas liquid chromatography are often
inconsistent and unreliable. Several UV-methods are
available for the analysis of barbiturates in serum or
urine. They all usually have one characteristic in common,
i. e. that of being rather laborious and time-consuming
(4,7,8,9).
When devising the principle described here, the intention
was to devise a method for analysis involving as few
manipulations and reagents as possible, yet giving
clinically fully acceptable results. The basis for our pro-
cedure is Goldbaum's method (4) which we improved
with several modifications, including a single extraction
technique with dichloroethane; this has resulted in a very
simple yet accurate method. The whole analysis takes
less than 20 minutes. One of the most serious compli-
cations of direct solvent extraction methods is the forma-
tion of emulsions. We found that chloroform is worse
than dichloroethane in this respect. A good general rule
is to ensure that the solvent volume is much larger than
the sample volume. In our method we found a ratio of
12.5:1 to be the most suitable. We used NH4C1 (300 g/1)
for adjusting the pH to 10.5 in a reference cuvette,
instead of boric acid-KCl solution, since this eliminates
the crystallization at room temperature.
Immunoassay techniques (Radioimmunoassay and
Enzyme Multiplied Immunoassay Technique) are more
effective in detecting barbiturates than is the spectro-
photometric technique or the gas-chrornatographic
technique. They are more rapid, and therefore con-
venient for screening purposes. Enzyme immuno-
assay now enables nearly any laboratory to perform fast,
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convenient, quantitative serum determinations of the
drug. Five different antiepileptic drugs can be assayed
from one 50 μΐ serum sample prepared from a "finger
stick" blood specimen. However, the lack of specifity
exhibited by the immunoassay methods and high price
of reagents are a distinct disadvantage (10). Severe
hemolytic, lipemic or icteric samples may cause poor
reproducibility and questionable quantitation when
immunochemical methodology is used (10). With our
method, addition of known concentrations of pheno-
barbital to highly lipemic or severe hemolytic sera
resulted in absorbance curves that were identical to
those for the corresponding standards.
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